NO20055979L - Sykliske sulfonamider for inhibering av gamma-secretase - Google Patents
Sykliske sulfonamider for inhibering av gamma-secretaseInfo
- Publication number
- NO20055979L NO20055979L NO20055979A NO20055979A NO20055979L NO 20055979 L NO20055979 L NO 20055979L NO 20055979 A NO20055979 A NO 20055979A NO 20055979 A NO20055979 A NO 20055979A NO 20055979 L NO20055979 L NO 20055979L
- Authority
- NO
- Norway
- Prior art keywords
- inhibition
- gamma secretase
- cyclic sulfonamides
- sulfonamides
- cyclic
- Prior art date
Links
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title abstract 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title abstract 2
- -1 Cyclic sulfonamides Chemical class 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Forbindelser ifølge formel (1) inhiberer prosesseringen av APP av gamma-sekretase og er følgelig anvendelig ved behandling eller forebygging av Alzheimers sykdom.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0311341A GB0311341D0 (en) | 2003-05-16 | 2003-05-16 | Therapeutic agents |
| GB0327055A GB0327055D0 (en) | 2003-11-20 | 2003-11-20 | Therapeutic agents |
| PCT/GB2004/002013 WO2004101539A1 (en) | 2003-05-16 | 2004-05-07 | Cyclic sulfonamides for inhibition of gamma-secretase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20055979L true NO20055979L (no) | 2006-02-15 |
Family
ID=33420897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20055979A NO20055979L (no) | 2003-05-16 | 2005-12-15 | Sykliske sulfonamider for inhibering av gamma-secretase |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7410964B2 (no) |
| EP (2) | EP1644346A1 (no) |
| JP (1) | JP4818114B2 (no) |
| KR (1) | KR20060013404A (no) |
| AT (1) | ATE386028T1 (no) |
| AU (1) | AU2004238607B2 (no) |
| BR (1) | BRPI0409969A (no) |
| CA (1) | CA2525841C (no) |
| DE (1) | DE602004011767T2 (no) |
| IL (1) | IL171977A (no) |
| IS (1) | IS8058A (no) |
| MX (1) | MXPA05012323A (no) |
| NO (1) | NO20055979L (no) |
| NZ (1) | NZ542797A (no) |
| RU (1) | RU2334743C2 (no) |
| WO (2) | WO2004101538A1 (no) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0108591D0 (en) | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
| GB0120347D0 (en) | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
| GB0223039D0 (en) | 2002-10-04 | 2002-11-13 | Merck Sharp & Dohme | Therapeutic compounds |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| KR20060013404A (ko) * | 2003-05-16 | 2006-02-09 | 머크 샤프 앤드 돔 리미티드 | γ-세크레타제 억제용 사이클릭 설폰아미드 |
| WO2006050359A2 (en) | 2004-11-02 | 2006-05-11 | Northwestern University | Pyridazine compounds and methods |
| EP1888078A2 (en) * | 2005-05-17 | 2008-02-20 | Merck Sharp & Dohme Ltd. | Sulphone derivatives for treatment of cancer |
| US8362075B2 (en) | 2005-05-17 | 2013-01-29 | Merck Sharp & Dohme Corp. | Cyclohexyl sulphones for treatment of cancer |
| GB0512049D0 (en) * | 2005-06-14 | 2005-07-20 | Merck Sharp & Dohme | Chemical process |
| MX2008009414A (es) | 2006-01-20 | 2008-10-01 | Schering Corp | Arilsulfonas carbociclicas y heterociclicas como inhibidores de gamma secretasa. |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| EP2121633A2 (en) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
| EP2481408A3 (en) | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| CN101754960A (zh) | 2007-07-05 | 2010-06-23 | 先灵公司 | 四氢吡喃并色烯γ-分泌酶抑制剂 |
| CA2693216A1 (en) * | 2007-07-17 | 2009-01-22 | Schering Corporation | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors |
| US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| EP2375895A4 (en) * | 2008-12-11 | 2012-05-30 | Merck Sharp & Dohme | METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS |
| WO2010114780A1 (en) | 2009-04-01 | 2010-10-07 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| JP5099731B1 (ja) | 2009-10-14 | 2012-12-19 | メルク・シャープ・アンド・ドーム・コーポレーション | p53活性を増大する置換ピペリジン及びその使用 |
| US20120295923A1 (en) * | 2010-01-29 | 2012-11-22 | Pfizer Inc. | Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| US8269019B2 (en) | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| AU2011285909B2 (en) | 2010-08-02 | 2016-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) |
| EP2606134B1 (en) | 2010-08-17 | 2019-04-10 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| EP2654748B1 (en) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP3358013B1 (en) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| KR20150060724A (ko) | 2012-09-28 | 2015-06-03 | 머크 샤프 앤드 돔 코포레이션 | Erk 억제제인 신규 화합물 |
| DK2925888T3 (en) | 2012-11-28 | 2017-12-18 | Merck Sharp & Dohme | COMPOSITIONS AND METHODS OF CANCER TREATMENT |
| EP2935263B1 (en) | 2012-12-20 | 2018-12-05 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2018071283A1 (en) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| EP3833668B1 (en) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| BR112021002267A8 (pt) | 2018-08-07 | 2023-02-07 | Merck Sharp & Dohme | Inibidores de prmt5 |
| EP4076459B1 (en) | 2019-12-17 | 2026-04-29 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| CA3160153A1 (en) | 2019-12-17 | 2021-06-24 | Michelle Machacek | Prmt5 inhibitors |
| BR112022012015A2 (pt) | 2019-12-17 | 2022-08-30 | Merck Sharp & Dohme Llc | Inibidores de prmt5 |
| EP4076460B1 (en) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer |
| WO2022015670A1 (en) * | 2020-07-14 | 2022-01-20 | Nikang Therapeutics, Inc. | Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors |
| KR20250053961A (ko) | 2022-09-02 | 2025-04-22 | 머크 샤프 앤드 돔 엘엘씨 | 엑사테칸-유래 토포이소머라제-1 억제제 제약 조성물 및 그의 용도 |
| TW202432099A (zh) | 2022-10-25 | 2024-08-16 | 美商默沙東有限責任公司 | 源自依克沙替康(exatecan)之adc連接子-載藥(payload)、醫藥組合物及其用途 |
| IL321395A (en) | 2022-12-14 | 2025-08-01 | Merck Sharp & Dohme Llc | Auristatin cargo-linkers, pharmaceutical compounds, and their uses |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2833776A (en) * | 1958-05-06 | Aryl-substituted psperidylpropanols | ||
| US3992536A (en) * | 1972-11-11 | 1976-11-16 | Boehringer Ingelheim Gmbh | Pharmaceutical compositions containing a 1-phenyl-2,2,4,4-C1 -C2 alkyl-3-[4-phenyl of pyridyl)-piperazino]-cyclobutanol-(1) and method of use |
| US3869434A (en) * | 1973-11-19 | 1975-03-04 | Phillips Petroleum Co | Soluble arylene sulfide polymers |
| DE2528285A1 (de) * | 1975-06-25 | 1977-01-20 | Basf Ag | Verfahren zur herstellung von 1,2,4-dihydrotriazin-4-oxid-spiro- (3,1')- eckige klammer auf oximino- (2')-cycloalkanen eckige klammer zu |
| FR2528433A1 (fr) * | 1982-06-15 | 1983-12-16 | Provesan Sa | Nouveaux derives d'oxazinobenzothiazine-6,6-dioxyde, leur preparation et leur application en tant que medicaments |
| DE3347126A1 (de) * | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE4035961A1 (de) * | 1990-11-02 | 1992-05-07 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| EP1000066A1 (en) * | 1997-07-16 | 2000-05-17 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine derivatives, their preparation and use |
| MXPA01008606A (es) | 1999-02-26 | 2003-05-05 | Merck & Co Inc | Compuestos de sulfonamida novedosos y uso de los mismos. |
| CA2404125C (en) * | 2000-03-20 | 2011-01-25 | Merck Sharp & Dohme Limited | Sulphonamido-substituted bridged bicycloalkyl derivatives |
| FR2812291B1 (fr) * | 2000-07-28 | 2002-12-13 | Adir | Nouveaux derives de benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| ES2248397T3 (es) | 2000-11-02 | 2006-03-16 | MERCK SHARP & DOHME LTD. | Sulfamidas como inhibidores de la gamma-secretasa. |
| GB0108591D0 (en) | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
| GB0108592D0 (en) * | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
| US7399775B2 (en) | 2001-12-27 | 2008-07-15 | Daiichi Pharmaceutical Co., Ltd. | β-amyloid protein production/secretion inhibitor |
| KR20060013404A (ko) * | 2003-05-16 | 2006-02-09 | 머크 샤프 앤드 돔 리미티드 | γ-세크레타제 억제용 사이클릭 설폰아미드 |
-
2004
- 2004-05-07 KR KR1020057021877A patent/KR20060013404A/ko not_active Ceased
- 2004-05-07 BR BRPI0409969-9A patent/BRPI0409969A/pt not_active IP Right Cessation
- 2004-05-07 AU AU2004238607A patent/AU2004238607B2/en not_active Ceased
- 2004-05-07 WO PCT/GB2004/001973 patent/WO2004101538A1/en not_active Ceased
- 2004-05-07 AT AT04731659T patent/ATE386028T1/de not_active IP Right Cessation
- 2004-05-07 JP JP2006530479A patent/JP4818114B2/ja not_active Expired - Fee Related
- 2004-05-07 US US10/555,034 patent/US7410964B2/en not_active Expired - Lifetime
- 2004-05-07 EP EP04731671A patent/EP1644346A1/en not_active Withdrawn
- 2004-05-07 NZ NZ542797A patent/NZ542797A/en not_active IP Right Cessation
- 2004-05-07 EP EP04731659A patent/EP1638951B1/en not_active Expired - Lifetime
- 2004-05-07 DE DE602004011767T patent/DE602004011767T2/de not_active Expired - Lifetime
- 2004-05-07 RU RU2005139398/04A patent/RU2334743C2/ru not_active IP Right Cessation
- 2004-05-07 CA CA2525841A patent/CA2525841C/en not_active Expired - Fee Related
- 2004-05-07 MX MXPA05012323A patent/MXPA05012323A/es active IP Right Grant
- 2004-05-07 WO PCT/GB2004/002013 patent/WO2004101539A1/en not_active Ceased
- 2004-05-14 US US10/845,833 patent/US7342009B2/en not_active Expired - Lifetime
-
2005
- 2005-09-30 IS IS8058A patent/IS8058A/is unknown
- 2005-11-15 IL IL171977A patent/IL171977A/en not_active IP Right Cessation
- 2005-12-15 NO NO20055979A patent/NO20055979L/no not_active Application Discontinuation
-
2007
- 2007-08-01 US US11/888,450 patent/US20080045515A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1638951A1 (en) | 2006-03-29 |
| AU2004238607B2 (en) | 2010-05-27 |
| KR20060013404A (ko) | 2006-02-09 |
| DE602004011767D1 (de) | 2008-03-27 |
| IL171977A0 (en) | 2006-04-10 |
| WO2004101539A1 (en) | 2004-11-25 |
| RU2334743C2 (ru) | 2008-09-27 |
| DE602004011767T2 (de) | 2009-02-19 |
| EP1644346A1 (en) | 2006-04-12 |
| RU2005139398A (ru) | 2006-04-10 |
| ATE386028T1 (de) | 2008-03-15 |
| BRPI0409969A (pt) | 2006-04-25 |
| EP1638951B1 (en) | 2008-02-13 |
| JP2006528961A (ja) | 2006-12-28 |
| MXPA05012323A (es) | 2006-01-30 |
| US20080045515A1 (en) | 2008-02-21 |
| US20040230054A1 (en) | 2004-11-18 |
| AU2004238607A1 (en) | 2004-11-25 |
| JP4818114B2 (ja) | 2011-11-16 |
| CA2525841A1 (en) | 2004-11-25 |
| WO2004101538A1 (en) | 2004-11-25 |
| US7410964B2 (en) | 2008-08-12 |
| NZ542797A (en) | 2007-12-21 |
| IS8058A (is) | 2005-09-30 |
| IL171977A (en) | 2010-12-30 |
| US7342009B2 (en) | 2008-03-11 |
| US20060281737A1 (en) | 2006-12-14 |
| CA2525841C (en) | 2012-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE368031T1 (de) | Neue gamma secretase inhibitoren | |
| MXPA05012323A (es) | Sulfonamidas ciclicas para la inhibicion de gama-secretasa. | |
| DE60112957D1 (de) | Sulfamide als gamma-secretase-inhibitoren | |
| DE60329533D1 (de) | Cyclische sulfamide zur inhibierung von gamma-sekretase | |
| ATE354563T1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| ATE494893T1 (de) | Sulfonamide, sulfamate und sulfamide als gamma- secretase-hemmer | |
| DE60328182D1 (de) | Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| DE602004009295D1 (de) | 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie | |
| DE60134874D1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
| NO20053627L (no) | Malonamidderivater som gamma-sekretase inhibitorer | |
| NO20083598L (no) | Karbosykliske og heterosykliske arylsulfoner som inhibitorer av gamma-sekretase | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| BR0308243A (pt) | Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero | |
| NO20063449L (no) | Substituerte heterocykler og deres anvendelse | |
| MXPA05012268A (es) | N-arilsulfonilpiperidinas enlazadas como inhibidores de la gamma-secretasa. | |
| NO20081843L (no) | Farmasoytisk sammensetning for forbedret kognitiv funksjon | |
| NO20050701L (no) | 4-pyrrolidino-fenyl-benzyleter derivater | |
| DE602004011255D1 (de) | Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit | |
| EA200801481A1 (ru) | 5-(арилсульфонил)пиразолопиперидины | |
| DE602004006118D1 (de) | 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER | |
| ATE530525T1 (de) | Piperidine und verwandte verbindungen zur behandlung von demenz | |
| ATE512147T1 (de) | Makrozyklische aminiopyridyl-beta-sekretase- hemmer zur behandlung von morbus alzheimer | |
| ATE556053T1 (de) | Piperidinderivate zur behandlung von alzheimer- krankheit | |
| NO20055750L (no) | Nye kjemiske forbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |